Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIVHeMA intraventricular fibrinolysis vs external ventricular drainage in aneurysmal subarachnoid hemorrhage
2017-000429-10Phase 3Completed
- Sponsor
- CHU Caen Normandie
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tissue-plasminogen activator in subarachnoid hemorrhage (SAH) and hydrocephalus (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Functional outcome at 6 months. Started Sep 2017; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
subarachnoid hemorrhage (SAH)hydrocephalus
Beyond the preview
Go deeper on 2017-000429-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000429-10.